Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Fusion protein, encoding nucleic acid and cell and use thereof

A fusion protein and cell technology, which is applied in the field of immunosuppressants to relieve immunosuppression, can solve the problems of slow disease progression and achieve the effect of enhancing anti-tumor function

Active Publication Date: 2020-12-11
启辰生生物科技(珠海)有限公司
View PDF12 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

For example, the use of CD223-targeted drugs and pembrolizumab (PD-1 monoclonal antibody) phase I clinical dose-escalation treatment of unresectable or metastatic melanoma has been published, and 50% of patients had tumor reduction, including 1 case with confirmed complete remission , had received pembrolizumab alone in medical records, but the disease progressed slowly

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Fusion protein, encoding nucleic acid and cell and use thereof
  • Fusion protein, encoding nucleic acid and cell and use thereof
  • Fusion protein, encoding nucleic acid and cell and use thereof

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0043] The method for preparing the cells of the present invention is not particularly limited. In an exemplary preparation method, the preparation method of the cell of the present invention comprises the following steps:

[0044] (1) Construct a nucleic acid capable of producing a fusion protein;

[0045] (2) Peripheral blood mononuclear cells are isolated from venous blood and induced to differentiate to obtain antigen-presenting cells; and

[0046] (3) introducing the nucleic acid of step (1) into the antigen-presenting cells of step (2), and culturing the antigen-presenting cells under conditions suitable for expression of the nucleic acid.

[0047] In certain embodiments, the methods of the invention comprise preparing a plasmid comprising DNA encoding the corresponding. Afterwards, the in vitro transcription process is carried out. Firstly, the plasmid is linearized with a restriction endonuclease, and the ribonucleic acid molecule is prepared by in vitro transcriptio...

Embodiment 1

[0056] This preparation example is a method for preparing an exemplary fusion protein.

[0057] 1. Preparation of DNA and mRNA Constructs

[0058] The gene used to generate an exemplary fusion protein of the present invention is constructed, and its sequence is shown in SEQ ID No. 5. In addition, genes used to produce soluble immunoglobulin CD223 and soluble programmed death receptor 1 as controls were further constructed, and their sequences are shown in SEQ ID No. 6 and 7, respectively. In addition, the antigen GPC3 used in subsequent experiments is encoded by the sequence shown in SEQ ID No. 8. The sequence information is shown in Table 1 below.

[0059] Table-1 DNA sequence list

[0060]

[0061] 2. In vitro transcription

[0062] Firstly, the prepared corresponding DNA plasmid was linearized using restriction endonuclease, and the linearized plasmid was used as a template, and T7 RNA polymerase was used to transcribe in vitro to prepare mRNA. The prepared mRNA was...

Embodiment 2

[0075] The experiment was performed in the same manner as in Example 1 except that the antigen in Example 1 was changed to AFP. The results are shown in the table below.

[0076] T cell control group mDC control AFP group AFP + PD-1 group AFP + CD223 group AFP+CD223-PD-1 group CD8 IFN-r+ 0.049 0.026 0.029 0.064 0.248 0.46 CD8 TNF-a+ 0.049 0 0 0.021 0.262 0.236 CD8 TNF-a+, IFN-r+ 0.049 0 0 0 0.18 0.15 CD4 IFN-r+ 0.3 0.027 0 0.24 0.165 0.64 CD4 TNF-a+ 0.201 0.28 0.27 0.35 0.37 1 CD4 TNF-a+, IFN-r+ 0.15 0 0 0.13 0.14 0.14

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a fusion protein, a coding nucleic acid, a cell and application. The fusion protein of the present invention comprises a soluble immunoglobulin CD223 as a first part and a soluble programmed death receptor 1 as a second part. The first part is covalently linked to the second part through a linker. The fusion protein disclosed by the invention has a specific Y-shaped structure, so that the functions of the first part and the second part have a synergistic effect, a PD-1 signal channel can be blocked, and an LAG3 signal channel can be blocked, so that inhibition of the PD-1 / LAG3 signal channel on T cells after activation can be effectively relieved, and the anti-tumor function of the T cells is remarkably enhanced.

Description

technical field [0001] The present invention relates to the fields of immunology and medicine, in particular to a fusion protein used to block the immunosuppressive site of tumor cells, its encoding nucleic acid, and cells containing such fusion protein or nucleic acid, and as an immunosuppressant in releasing immunosuppression use. Background technique [0002] Since the first PD-1 antibody drug was launched on the market in 2015, this type of drug has shown excellent safety and efficacy. At present, combined drugs based on PD-1 and PDL-1 have become a new direction for tumor treatment, and some have been developed. Exciting data have also been obtained in the clinical combination drug research, and more and more people have confidence in the combination drug of immune checkpoints. [0003] PD-1 inhibitors include PD-1 antibodies and PD-L1 antibodies, and are a new drug for tumor immunotherapy. Unlike surgery, radiotherapy and chemotherapy, and targeted drugs, PD-1 inhibi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07K19/00C12N15/62C12N5/10A61K39/395A61P35/00A61K38/17
CPCA61K38/177A61K39/39558A61P35/00C07K14/705C07K14/70596C07K2319/00C12N5/0636C12N2510/00A61K2300/00
Inventor 蒋俊林鑫谢桦函
Owner 启辰生生物科技(珠海)有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com